Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 07/12/2020

    One for all

    AI-based evaluation of medical imaging data usually requires a specially developed algorithm for each task. Scientists from the German Cancer Research Center (DKFZ) have now presented a new method for configuring self-learning algorithms for a large number of different imaging datasets – without the need for specialist knowledge or very significant computing power.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/one-all
  • New method for analysing blood samples - 26/11/2020 Bildschirmfoto_2020-10-30_um_11.46.25.png

    Personalised therapy monitoring for malignant melanomas

    Immunotherapy has greatly improved the survival chances of patients with malignant melanoma. A study has now begun at the Department of Dermatology at the University Hospital of Tübingen to develop a way to monitor the course of treatment as effectively as possible. It involves personalised monitoring using liquid biopsies in addition to conventional PET/CT examinations. This analysis procedure of blood samples could enable closer monitoring of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/personalised-therapy-monitoring-malignant-melanomas
  • Press release - 26/10/2020

    How to prevent the spread of tumor cells via the lymph vessels

    What role do the lymphatic vessels play in the metastasis of cancer cells? Scientists from the German Cancer Research Center and the Mannheim Medical Faculty of the University of Heidelberg developed a method to investigate this question in mice. The aim of the work was to identify new ways to block the dangerous colonization and spread of tumor cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-prevent-spread-tumor-cells-lymph-vessels
  • Press release - 12/08/2020

    New technology provides insight into the development of immune cells

    The entire range of our blood and immune cells are derived from hematopoietic stem cells. Yet which genes influence how they develop into the different cell types? Scientists from the German Cancer Research Center (DKFZ) have now developed a new technology to answer this question.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-technology-provides-insight-development-immune-cells
  • Vision Zero in oncology - 02/09/2019 Titelcover_Vision-Zero.jpg

    Call for a comprehensive master plan for preventing and treating cancer

    While a cancer-free world may seem unrealistic given the increasing numbers of cancer cases, we need to reach a social consensus that cancer deaths are unacceptable and that everything possible must be done to prevent them. Leading cancer researchers around the world are calling for more investment in prevention research and cancer screening to move towards the vision of a near cancer-free world.

    https://www.gesundheitsindustrie-bw.de/en/article/news/call-for-comprehensive-master-plan-preventing-treating-cancer
  • New edition - 24/05/2019 Magnetic resonance image of brain metastases.

    Tumour metastasis

    Cancer is usually not curable when metastases have formed in the body. Metastases are often resistant to drugs that have successfully eliminated the primary tumour. The basic features of the complex process of metastasis are now known, but many details still remain elusive. Intensive research activities are focusing on new therapeutic concepts aimed at developing effective anti-metastatic therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/tumour-metastasis
  • Article - 16/04/2019 20190218_Foto_Labor_Quelle_UniversitNatsklinikum_Heidelberg.jpg

    Tumour monitoring using liquid biopsy

    Liquid biopsy, the analysis of cancer biomarkers and circulating tumour cells in body fluids such as blood, is revolutionising the diagnosis and monitoring of cancer. It has also been possible to expand circulating tumour cells from the blood under laboratory conditions. It is expected that in the future, liquid biopsy will be able to precisely characterise tumour cells at every stage of a cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/tumour-monitoring-using-liquid-biopsy
  • Article - 22/03/2019 Prof. Lichter (left) and Prof. Schneeweiss, who run the Translational Breast Cancer Programme in Heidelberg, in the laboratory

    Personalised therapies for treating metastasing breast cancer

    Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements.

    https://www.gesundheitsindustrie-bw.de/en/article/news/personalisierte-therapieansaetze-bei-metastasiertem-brustkrebs
  • Dossier - 28/08/2018 Woman wearing a white lab coat in a laboratory looking at a tube she is holding in her hand.

    With molecular diagnostics to biomarker-based personalised therapy

    Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/with-molecular-diagnostics-to-biomarker-based-personalised-therapy
  • Article - 18/01/2018 Teaser-Mutationen-Primartumor.png

    Medications that target metastasing tumours

    Tumour metastases are often resistant to the drug that is used to eliminate the primary tumour. Genome-wide analyses of mutation patterns in the primary tumour and its metastases provide information on the aggressiveness of cancer and may help to find the best available means of further treatment. This has been demonstrated by scientists from Heidelberg in a clinical trial on the molecular evolution of renal cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/medications-that-target-metastasing-tumours
  • Article - 11/12/2017 The photo shows a man with glasses holding a blue cord with flags and marks in his hands.

    KDM4 – an efficient target for the therapy of triple-negative breast cancer

    While breast cancer survival has clearly improved in recent years, women with triple-negative breast cancer have benefitted very little from progress in cancer medicine. Targeted therapies aimed at inhibiting epigenetic regulators might offer a potential new option for the treatment of breast cancer. Prof. Dr. Roland Schüle and Dr. Jochen Maurer have discovered an epigenetic enzyme called KDM4 and come up with a new cell model that significantly…

    https://www.gesundheitsindustrie-bw.de/en/article/news/kdm4-an-efficient-target-for-the-therapy-of-triple-negative-breast-cancer
  • Article - 31/05/2017 The tumours can be removed using peritonectomies with HIPEC.

    Peritoneal cancer – long-term survival with good quality of life

    Thanks to an innovative treatment procedure that has been in use since 2005, surgeons from Tübingen University Hospital have been able to prolong the survival of patients with peritoneal cancer and give them a higher quality of life. This is done using a technique based on complex surgery followed by immediate intraoperative local chemotherapy on the peritoneum.

    https://www.gesundheitsindustrie-bw.de/en/article/news/peritoneal-cancer-long-term-survival-with-good-quality-of-life
  • Press release - 14/12/2016

    amcure Raises €6 Million in Series B Financing and Expands Advisory Board

    Eggenstein-Leopoldshafen – 14 December 2016: amcure, a biopharmaceutical company developing first-in-class cancer therapeutics, today announced the closing of a Series B financing round amounting to a total of EUR 6 million.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/amcure-raises-6-million-in-series-b-financing-and-expands-advisory-board
  • Article - 05/09/2016 Glioblastom_MRT.jpg

    Apogenix: immuno-oncological protein drugs for the treatment of malignant diseases

    Apogenix AG, a biopharmaceutical company from Heidelberg that specialises in immuno-oncology, develops protein drugs that target central signalling pathways involved in regulating the growth, migration and apoptosis of malfunctioning cells and thus offer novel treatment options for cancer and other malignant diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/news/apogenix-immunonkologische-proteinwirkstoffe-gegen-maligne-erkrankungen
  • Article - 22/08/2016 Schematic of a modified virus.

    Ad-O-Lytics – a new biotech start-up from Ulm

    A few years ago, Florian Kreppel developed a therapeutic approach that combined genetic vaccines with molecular address labels. It worked quite well, but the resulting product did not have the anticipated immunising properties and was put on the backburner. Now Kreppel's group of researchers is nearing completion of another project. The researchers plan to use a patented virotherapeutic platform technology for cancer treatment to establish a…

    https://www.gesundheitsindustrie-bw.de/en/article/news/ad-o-lytics-a-new-biotech-start-up-from-ulm
  • Article - 11/07/2016 riesenmitochondrien.jpg

    The toxin of natural killer cells

    Natural killer cells kill tumour cells by injecting the protein HMGB1, which blocks the production of cellular energy by aerobic respiration. Researchers from Heidelberg have elucidated this previously unknown cancer defence mechanism and are now in the process of developing a new immunotherapy for treating cancer patients.

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-toxin-of-natural-killer-cells
  • Article - 04/07/2016 The schematic shows how oesophageal cells develop into the two major types of oesophageal cancer.

    Epigenetic modifications for the treatment of oesophageal cancer

    Oesophageal cancer is a rare but highly aggressive type of cancer with a rather poor prognosis. Dr. Theresa Ahrens, a researcher in a group led by Prof. Dr. Silke Laßmann and Prof. Dr. Martin Werner at the Institute of Clinical Pathology at the Freiburg University Medical Centre, has tested a variety of epigenetic drugs that can interfere with the development of oesophageal cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/modifikation-epigenetic-modifications-for-the-treatment-of-oesophageal-cancer-als-therapie-bei-speiseroehrenkrebs
  • Article - 20/06/2016 NCT_Heidelberg.jpg

    Activation of the innate immune system against metastatic colorectal cancer

    Researchers from Heidelberg have shown that instead of fighting cancer cells, macrophages of the innate immune system promote the growth of metastases in people with metastatic colorectal cancer. They have also shown that a signal inhibitor used to treat HIV infections reactivates macrophages so that they gain the ability to destroy cancer cells. A clinical phase I study has confirmed the antitumoral effects of this drug.

    https://www.gesundheitsindustrie-bw.de/en/article/news/activation-of-the-innate-immune-system-against-metastatic-colorectal-cancer
  • Article - 26/04/2016 Photo showing a bottle with medicine that is dropped onto a spoon.

    Methadone for cancer treatment? Clinical trials are needed to prove the effectiveness of this opioid

    Claudia Friesen, an oncologist at Ulm University Hospital, has achieved what many scientists dream of: she has made a discovery that has increased existing knowledge, and can be used to help people. People with cancers that are resistant to all conventional therapies who have been given methadone for pain relief in combination with conventional chemo- or radiation therapy, have reported that tumours have shrunk or disappeared completely. Clinical…

    https://www.gesundheitsindustrie-bw.de/en/article/news/methadone-for-cancer-treatment-clinical-trials-are-needed-to-prove-the-effectiveness-of-this-opioid
  • Article - 25/04/2016 Trumpp_Andreas.jpg

    Pancreatic cancer and its resistance to therapy

    Pancreatic tumours are among the cancers with the worst prognosis. In many cases they are resistant to treatment. Prof. Dr. Andreas Trumpp and his colleagues from the DKFZ and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine HI-STEM have discovered that the reason why some pancreatic tumours are so resistant to treatment is down to larger quantities of the enzyme CYP3A5 in subtypes of pancreatic cancer. Molecular…

    https://www.gesundheitsindustrie-bw.de/en/article/news/pancreatic-cancer-and-its-resistance-to-therapy
  • Medical technology - 14/03/2016 Experimenteller_Interventionsraum_mit_mobilen_Rontgengerat_Monitoren_und_OP-Tisch_an_dem_der_Interventionsassistent_herangefahren_werden_kann.jpg

    The operating room of the future: minimally invasive and future-oriented intervention techniques

    Being able to diagnose and treat tumour patients in just a few hours is just one of the many promising goals of the Fraunhofer Project Group for Automation in Medicine and Biotechnology (PAMB). The overall goal of the Intervention and Therapy research group is to take innovative technologies for diagnostic and therapeutic interventions from laboratory development to prototype production for use in clinical trials.

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-operating-room-of-the-future-minimally-invasive-and-future-oriented-intervention-techniques
  • Article - 14/12/2015 Fluorescence microscope image showing the degradation of the proteins.

    Cathepsin L: overcoming stress in tumours

    Cathepsins are proteases, i.e. enzymes that break down proteins into smaller fragments. They are also involved in the formation of new blood vessels and wound healing. Another thing that cathepsins do is help tumours spread and form metastases in the body. Prof. Dr. Thomas Reinheckel and his team from the Institute of Molecular Medicine and Cell Research at the University of Freiburg are studying how this happens. Insights into the role of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/cathepsin-l-den-stress-im-tumor-ueberwinden
  • Article - 20/07/2015 Fluorescence microscope image of cells. The photo on the left shows a stationary cell layer with red circles and red boundaries; the photo on the right shows red circles against a blurred green background.

    How cells communicate with each other

    The ability of cells to move around as a cohesive group and communicate with each other plays a major role in many vital processes, including wound healing and embryo development. One cell becomes a lead cell and determines the direction that follower cells take. Researchers led by biophysicist Joachim Spatz from the Max Planck Institute for Intelligent Systems in Stuttgart have successfully decoded the collective movement of cells in the body.…

    https://www.gesundheitsindustrie-bw.de/en/article/news/how-cells-communicate-with-each-other
  • Article - 26/05/2015 The photo shows two scientists looking into the camera.

    Novel effect of B-Raf inhibitors against bowel cancer discovered

    Colorectal carcinoma is the most frequent type of bowel cancer and the second most common tumour disease in men and women in Germany. A particularly aggressive form occurs when a mutation is present in the proto-oncogene BRAF. As part of the Collaborative Research Centre 850 at the Institute of Molecular Medicine and Cell Research at the University of Freiburg, Dr. Ricarda Herr and Dr. Tilman Brummer are trying to find out how a mutated BRAF gene…

    https://www.gesundheitsindustrie-bw.de/en/article/news/novel-effect-of-b-raf-inhibitors-against-bowel-cancer-discovered
  • Article - 11/05/2015 Microscopic image of MTSS1 expression.

    Lung cancer: MTSS1 is a putative marker of tumour progression and metastatic disease

    Lung cancer is one of the most common malignant diseases and one of the leading causes of cancer-related deaths worldwide. 90% of all lung cancer cases in men and 80% in women are due to long-term exposure to tobacco smoke. In Germany, around 140 new cases are diagnosed every day, and 50,000 people die of lung cancer every year. PD Dr. Gian Kayser, senior consultant in the Department of Clinical Pathology at Freiburg University Medical Centre,…

    https://www.gesundheitsindustrie-bw.de/en/article/news/lung-cancer-mtss1-is-a-putative-marker-of-tumour-progression-and-metastatic-disease

Page 1 / 3

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2021
Website address: https://www.gesundheitsindustrie-bw.de/en/search